AU Patent

AU2014202306B2 — Controlled release formulations of levodopa and uses thereof

Assigned to Impax Laboratories LLC · Expires 2016-09-08 · 10y expired

What this patent protects

CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled relea…

USPTO Abstract

CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014202306B2
Jurisdiction
AU
Classification
—
Expires
2016-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.